Dr. Lal Pathlabs

₹1825.9 -3.7 | 0.2%

WEBSITE BSE:539524 NSE : LALPATHLAB 23 Mar, 16:01

Market Cap ₹15231 Cr.

Stock P/E 62.5

P/B 9.5

Current Price ₹1825.9

Book Value ₹ 192.3

Face Value 10

52W High ₹2878.6

Dividend Yield 0.66%

52W Low ₹ 1762.7

Edit Ratio

Dr. Lal Pathlabs Research see more...

EQUITY RESEARCH: DR LALPATHLABS

Overview Inc. Year: 1995Industry: Hospital & Healthcare Services

Dr. Lal PathLabs Ltd is an India-based organisation, that is engaged in offering diagnostic and associated healthcare assessments and offerings. It has a community that have a National Reference Laboratory in New Delhi, a Reference Laboratory in Kolkata and approximately 229 other clinical laboratories. The Company is engaged specially within the enterprise of strolling laboratories for carrying out pathological investigations of diverse branches of biochemistry, haematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and different pathological and radiological investigations. The Company offers various tests by condition, which incorporates allergic reaction, diabetes, health checkups, viral infections, fever, heart sicknesses, high blood pressure, cancer, abortions, anaemia, arthritis, breast cancer, diphtheria, disease of liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular sickness and viral infections.

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Dr. Lal Pathlabs Quarterly Results

#(Fig in Cr.)	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Net Sales	432	452	431	607	498	497	486	503	534	489
Other Income	13	14	14	14	14	12	12	8	9	11
Total Income	445	466	445	621	513	509	498	511	543	500
Total Expenditure	305	314	309	418	357	388	364	385	390	376
Operating Profit	140	152	136	203	156	121	133	126	153	124
Interest	4	4	4	5	5	9	12	9	11	9
Depreciation	20	20	20	19	21	31	38	36	39	38
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	117	129	111	179	131	82	84	81	103	77
Provision for Tax	30	33	26	46	34	23	21	23	30	23
Profit After Tax	87	96	85	134	96	58	62	58	72	54
Adjustments	-2	-1	-2	-3	-1	-1	-1	-1	-1	-1
Profit After Adjustments	85	95	83	131	95	57	61	58	72	53
Adjusted Earnings Per Share	10.2	11.3	10	15.8	11.4	6.9	7.4	6.9	8.6	6.3

Dr. Lal Pathlabs Profit & Loss

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	TTM
Net Sales	342	452	558	660	791	912	1057	1203	1330	1581	2087	2012
Other Income	2	3	8	13	22	28	31	46	55	51	53	40
Total Income	344	455	566	673	813	940	1088	1249	1385	1633	2140	2052
Total Expenditure	256	354	419	504	584	675	793	910	987	1145	1527	1515
Operating Profit	89	101	147	168	229	265	295	340	399	488	613	536
Interest	3	0	0	0	0	1	1	1	15	16	30	41
Depreciation	20	20	27	28	28	28	33	38	73	77	108	151
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	66	80	119	140	201	237	261	301	311	394	475	345
Provision for Tax	21	25	39	43	67	81	90	100	83	98	125	97
Profit After Tax	45	56	80	96	133	156	172	200	228	296	350	246
Adjustments	-0	-1	-1	-1	-1	-1	-1	-1	-2	-5	-5	-4
Profit After Adjustments	45	55	80	96	132	155	171	199	226	292	345	244
Adjusted Earnings Per Share	0	0	0	0	16	18.6	20.5	23.9	27.1	35	41.4	29.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	32%	20%	18%	20%
Operating Profit CAGR	26%	22%	18%	21%
PAT CAGR	18%	21%	18%	23%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-31%	13%	16%	NA%
ROE Average	26%	26%	25%	32%
ROCE Average	33%	34%	35%	45%

Dr. Lal Pathlabs Balance Sheet

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Shareholder's Funds	116	162	231	341	507	596	788	945	1033	1245	1508
Minority's Interest	1	2	2	2	3	2	4	5	21	31	35
Borrowings	0	0	0	0	0	0	0	0	0	0	167
Other Non-Current Liabilities	8	3	1	-5	12	-6	-9	-20	70	83	106
Total Current Liabilities	49	89	97	112	91	85	116	138	227	274	500
Total Liabilities	174	256	332	450	613	676	899	1069	1351	1633	2316
Fixed Assets	108	127	140	150	166	152	208	209	413	447	1375
Other Non-Current Assets	24	13	22	18	24	57	68	47	46	41	66
Total Current Assets	42	117	170	282	424	467	623	814	893	1145	875
Total Assets	174	256	332	450	613	676	899	1069	1351	1633	2316

Dr. Lal Pathlabs Cash Flow

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Opening Cash & Cash Equivalents	4	8	17	16	23	27	29	66	129	197	244
Cash Flow from Operating Activities	68	88	98	122	159	171	197	219	284	398	447
Cash Flow from Investing Activities	-26	-65	-90	-113	-163	-137	-172	-100	-26	-212	-449
Cash Flow from Financing Activities	-38	-15	-10	-1	0	-32	13	-55	-190	-139	136
Net Cash Inflow / Outflow	4	8	-2	8	-5	2	37	64	67	48	134
Closing Cash & Cash Equivalent	8	17	16	23	19	29	66	129	197	244	378

Dr. Lal Pathlabs Ratios

#	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Earnings Per Share (Rs)	0	0	0	0	15.99	18.61	20.49	23.9	27.11	34.99	41.37
CEPS(Rs)	12.11	14.17	20.03	22.81	19.54	22.05	24.58	28.64	36.04	44.83	55
DPS(Rs)	25.7	15.4	1.1	1.53	2.45	3	4.5	6	12	20	12
Book NAV/Share(Rs)	0	0	0	0	61.28	70.66	92.39	110.08	119.97	144.61	173.95
Core EBITDA Margin(%)	25.28	21.62	24.83	23.52	26.24	26.03	24.98	24.4	25.83	27.59	26.86
EBIT Margin(%)	20.15	17.85	21.4	21.24	25.43	26.03	24.8	25.04	24.49	25.95	24.2
Pre Tax Margin(%)	19.41	17.76	21.37	21.18	25.36	25.96	24.72	24.97	23.34	24.94	22.75
PAT Margin (%)	13.2	12.32	14.39	14.62	16.84	17.05	16.25	16.66	17.11	18.75	16.78
Cash Profit Margin (%)	18.99	16.84	19.27	18.89	20.41	20.07	19.38	19.83	22.58	23.63	21.96
ROA(%)	26.45	25.86	27.3	24.67	25.06	24.13	21.81	20.38	18.81	19.87	17.74
ROE(%)	43.96	40.52	43.95	37.14	32.45	28.45	25.32	23.76	23.74	26.89	26.39
ROCE(%)	60.36	57.93	60.49	48.87	47.43	43.07	37.9	34.78	32.94	36.03	32.6
Receivable days	12.81	13.78	14.7	15.53	15.51	15.62	14.32	14.31	14.35	13.63	13.3
Inventory Days	7.46	6	6.64	7.18	6.64	6.49	7.81	8.47	11.73	11.49	8.31
Payable days	95.02	101.56	99.7	87.86	80.66	87.64	95.14	101.04	120.69	120.3	105.92
PER(x)	0	0	0	0	57.63	51.99	42.7	44.12	51.69	77.38	63.02
Price/Book(x)	0	0	0	0	15.04	13.69	9.47	9.58	11.68	18.72	14.99
Dividend Yield(%)	0	0	0	0	0.27	0.31	0.51	0.57	0.86	0.74	0.46
EV/Net Sales(x)	-0.02	-0.04	-0.04	-0.1	9.36	8.55	6.6	6.9	8.35	13.68	10.28
EV/Core EBITDA(x)	-0.09	-0.16	-0.17	-0.4	32.28	29.42	23.63	24.43	27.87	44.38	34.99
Net Sales Growth(%)	44.23	31.98	23.53	18.22	19.97	15.3	15.84	13.86	10.55	18.86	32.01
EBIT Growth(%)	51.5	16.95	48.07	17.35	43.6	18.04	10.37	14.96	8.11	25.96	23.09
PAT Growth(%)	52.87	23.2	44.24	20.15	38.15	16.78	10.39	16.72	13.53	30.27	18.15
EPS Growth(%)	0	0	0	0	0	16.4	10.09	16.65	13.43	29.07	18.25
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0.24
Current Ratio(x)	0.86	1.31	1.75	2.52	4.67	5.5	5.37	5.88	3.93	4.18	1.75
Quick Ratio(x)	0.74	1.23	1.64	2.39	4.51	5.29	5.14	5.68	3.68	4.02	1.65
Interest Cover(x)	27.24	183.69	603.05	346.2	404.57	340.29	311.72	359.22	21.28	25.65	16.74
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0.02

Dr. Lal Pathlabs Shareholding Pattern

#	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Promoter	55.23	55.23	55.23	55.23	55.23	55.23	55.23	55.05	55.05	55.05
FII	22.42	24.37	26.01	26.42	26.82	25.45	23.44	22.37	23.26	25.8
DII	9.63	8.84	7.53	6.54	5.73	6.58	6.83	6.52	6.27	6.19
Public	12.73	11.56	11.24	11.81	12.22	12.75	14.5	16.06	15.43	12.96
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Promoter	4.6	4.6	4.6	4.6	4.6	4.6	4.6	4.59	4.59	4.59
FII	1.87	2.03	2.17	2.2	2.23	2.12	1.95	1.86	1.94	2.15
DII	0.8	0.74	0.63	0.55	0.48	0.55	0.57	0.54	0.52	0.52
Public	1.06	0.96	0.94	0.98	1.02	1.06	1.21	1.34	1.29	1.08
Others	0	0	0	0	0	0	0	0	0	0
Total	8.33	8.33	8.33	8.33	8.33	8.33	8.33	8.34	8.34	8.34